Published in J Neuroimmunol on March 01, 2003
Movement disorders in paraneoplastic and autoimmune disease. Curr Opin Neurol (2011) 1.28
Behavioral, pharmacological, and immunological abnormalities after streptococcal exposure: a novel rat model of Sydenham chorea and related neuropsychiatric disorders. Neuropsychopharmacology (2012) 1.23
Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage. J Immunol Res (2014) 1.01
Cytokine correlations in youth with tic disorders. J Child Adolesc Psychopharmacol (2015) 0.80
Clinical and Neuroimaging Findings of Sydenham's Chorea. Iran J Pediatr (2014) 0.75
Diffusion-weighted imaging in Sydenham's chorea. Childs Nerv Syst (2012) 0.75
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 11.29
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med (2012) 7.58
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med (2008) 6.90
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet (2005) 5.81
Microdeletion encompassing MAPT at chromosome 17q21.3 is associated with developmental delay and learning disability. Nat Genet (2006) 5.59
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol (2010) 5.03
A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res (2010) 4.77
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain (2002) 4.16
The likelihood of an indeterminate test result from a whole-blood interferon-gamma release assay for the diagnosis of Mycobacterium tuberculosis infection in children correlates with age and immune status. Pediatr Infect Dis J (2009) 3.86
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet (2010) 3.34
DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol (2008) 3.03
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol (2005) 2.94
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet (2013) 2.89
Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord (2004) 2.84
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol (2009) 2.82
The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann Neurol (2003) 2.80
Lack of association between progressive supranuclear palsy and arterial hypertension: a clinicopathological study. Mov Disord (2003) 2.69
Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain (2005) 2.67
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med (2007) 2.64
Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain (2003) 2.63
Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol (2003) 2.61
Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol (2006) 2.56
Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol (2005) 2.55
ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord (2010) 2.47
Evidence for acute neurotoxicity after chemotherapy. Ann Neurol (2010) 2.45
Parkin disease: a phenotypic study of a large case series. Brain (2003) 2.41
Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol (2009) 2.38
Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov Disord (2010) 2.36
Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol (2013) 2.36
The clinical significance of an intrathecal monoclonal immunoglobulin band: a follow-up study. Neurology (2003) 2.35
CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res (2003) 2.27
International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler (2013) 2.20
The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain (2004) 2.20
Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain (2010) 2.19
The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain (2003) 2.17
Testicular hypofunction and multiple sclerosis risk: a record-linkage study. Ann Neurol (2014) 2.09
Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol (2010) 2.08
Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease. Ann Neurol (2012) 2.08
Identical twins with Leucine rich repeat kinase type 2 mutations discordant for Parkinson's disease. Mov Disord (2012) 2.02
Endothelial dysfunction in childhood infection. Circulation (2005) 1.97
Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord (2007) 1.96
Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J Neurochem (2006) 1.91
A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain (2011) 1.89
Cortical hypometabolism demonstrated by PET in relapsing NMDA receptor encephalitis. Pediatr Neurol (2010) 1.89
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Increased incidence and severity of the systemic inflammatory response syndrome in patients deficient in mannose-binding lectin. Intensive Care Med (2004) 1.86
What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? Mov Disord (2010) 1.80
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol (2010) 1.80
Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord (2004) 1.76
α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol (2013) 1.75
Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord (2012) 1.75
The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology (2013) 1.74
Neuropathological findings in benign tremulous parkinsonism. Mov Disord (2012) 1.74
Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. Acta Neuropathol (2011) 1.71
The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Mult Scler (2012) 1.71
Natural history and syndromic associations of orthostatic tremor: a review of 41 patients. Mov Disord (2004) 1.69
Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med (2007) 1.69
Parkin disease: a clinicopathologic entity? JAMA Neurol (2013) 1.68
Early postoperative monocyte deactivation predicts systemic inflammation and prolonged stay in pediatric cardiac intensive care. Crit Care Med (2002) 1.68
Platelet and soluble CD40L in meningococcal sepsis. Intensive Care Med (2006) 1.67
Progressive supranuclear palsy: where are we now? Lancet Neurol (2002) 1.65
Neurologic complications of influenza A(H1N1)pdm09: surveillance in 6 pediatric hospitals. Neurology (2012) 1.65
The use of smell identification tests in the diagnosis of Parkinson's disease in Brazil. Mov Disord (2008) 1.65
Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol (2010) 1.64
Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord (2012) 1.63
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain (2003) 1.62
Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol (2012) 1.61
Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging (2010) 1.56
Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov Disord (2010) 1.56
Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol (2009) 1.55
Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation (2005) 1.54
Investigation of childhood central nervous system vasculitis: magnetic resonance angiography versus catheter cerebral angiography. Dev Med Child Neurol (2010) 1.53
Rhabdomyolysis after bariatric surgery by Roux-en-Y gastric bypass: a prospective study. Obes Surg (2008) 1.52
Enhancement of complement activation and opsonophagocytosis by complexes of mannose-binding lectin with mannose-binding lectin-associated serine protease after binding to Staphylococcus aureus. J Immunol (2002) 1.52
Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem (2012) 1.52
Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord (2007) 1.52
Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain (2007) 1.52
Genetic polymorphism of the binding domain of surfactant protein-A2 increases susceptibility to meningococcal disease. Clin Infect Dis (2006) 1.51
Clinical features of childhood-onset paroxysmal kinesigenic dyskinesia with PRRT2 gene mutations. Dev Med Child Neurol (2013) 1.51
J. Clifford Richardson and 50 years of progressive supranuclear palsy. Neurology (2008) 1.50
The therapeutic potential of cannabis. Lancet Neurol (2003) 1.49
Endothelial response to childhood infection: the role of mannose-binding lectin (MBL). Atherosclerosis (2009) 1.48
Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol (2003) 1.48
Endothelial injury in childhood stroke with cerebral arteriopathy: a cross-sectional study. Neurology (2012) 1.47
In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study. Exp Neurol (2010) 1.47
Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain (2006) 1.47
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler (2012) 1.46
Guthrie card methylomics identifies temporally stable epialleles that are present at birth in humans. Genome Res (2012) 1.45
Clinical association of intrathecal and mirrored oligoclonal bands in paediatric neurology. Dev Med Child Neurol (2012) 1.45
Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology (2014) 1.45
Low-molecular-weight polyethylene glycol improves survival in experimental sepsis. Crit Care Med (2010) 1.45
PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine. Neurology (2012) 1.44
Month of birth, vitamin D and risk of immune-mediated disease: a case control study. BMC Med (2012) 1.44